Explore

TrendlineTrendline
Oil of Oregano Lacks Robust Human Evidence for Health Claims, Posing Safety Concerns

Oil of Oregano Lacks Robust Human Evidence for Health Claims, Posing Safety Concerns

Oil of Oregano Lacks Robust Human Evidence for Health Claims, Posing Safety Concerns
TrendlineTrendline
Food Industry Innovates Sweeteners with AI and Natural Alternatives Amidst Health Concerns

Food Industry Innovates Sweeteners with AI and Natural Alternatives Amidst Health Concerns

Food Industry Innovates Sweeteners with AI and Natural Alternatives Amidst Health Concerns
TrendlineTrendline
Trilliome Introduces TRI-01, a Precision Activator for Keystone Gut Bacteria

Trilliome Introduces TRI-01, a Precision Activator for Keystone Gut Bacteria

Trilliome Introduces TRI-01, a Precision Activator for Keystone Gut Bacteria
Rapid ReadRapid Read
Gut Bacteria Molecule Indole Fights Food Poisoning Caused by Campylobacter jejuni

Gut Bacteria Molecule Indole Fights Food Poisoning Caused by Campylobacter jejuni

Researchers at Michigan State University have discovered that a molecule called indole, naturally produced by certain gut bacteria, can inhibit the growth of *Campylobacter jejuni* (Campy), a leading cause of bacterial food poisoning worldwide. The study, published in *Science Advances*, found that indole interferes with Campy's respiration and metabolism, making it difficult for the bacterium to generate and use energy for growth. The research also revealed that intestinal inflammation, often a response to infection, can reduce the levels of indole-producing microbes, thereby weakening the gut's natural defense against Campy. When indole levels were increased in mouse models, Campy colonization significantly decreased, and a probiotic bacterium that naturally produces indole also showed similar protective effects.
TrendlineTrendline
Boston Industrial Solutions Introduces Personalized Training for Pad and Screen Printing

Boston Industrial Solutions Introduces Personalized Training for Pad and Screen Printing

Boston Industrial Solutions Introduces Personalized Training for Pad and Screen Printing
Rapid ReadRapid Read
Fifteen State Attorneys General Challenge FERC Proposal to Expedite Natural Gas Projects

Fifteen State Attorneys General Challenge FERC Proposal to Expedite Natural Gas Projects

A coalition of 15 state attorneys general, led by Washington Attorney General Nick Brown and Massachusetts Attorney General Andrea Campbell, is urging the Federal Energy Regulatory Commission (FERC) to reconsider a proposal that would expand its blanket certificate program for natural gas projects. This program allows certain expansions or modifications to existing natural gas facilities to proceed without a separate, full certificate proceeding, aiming to reduce delays. While supporters argue that faster permitting could improve reliability and reduce construction costs, the attorneys general contend that expanding this program could lead to larger, more consequential projects receiving insufficient scrutiny. They warn that this reduced oversight could expose ratepayers to unnecessary costs and environmental risks, particularly if utilities later seek to recover these costs from customers without adequate justification for the project's necessity or cost-effectiveness. The debate centers on balancing the ...
Rapid ReadRapid Read
Cullinan and Taiho Plan FDA Filing for Lung Cancer Pill Zipalertinib Despite Patient Deaths

Cullinan and Taiho Plan FDA Filing for Lung Cancer Pill Zipalertinib Despite Patient Deaths

Taiho Oncology and Cullinan Therapeutics are moving forward with plans to file for FDA approval of their oral drug candidate, zipalertinib, for non-small cell lung cancer (NSCLC), despite three patient deaths reported during a late-stage study. The Phase 3 REZILIENT3 trial demonstrated that zipalertinib, when combined with chemotherapy, significantly improved progression-free survival (PFS) in patients with first-line advanced non-squamous NSCLC harboring exon 20 mutations to the EGFR gene. Patients receiving the zipalertinib regimen experienced a 50% reduction in the risk of death or disease progression, with a median PFS of 14.5 months compared to 8.5 months in the control group. While adverse events of grade 3 or higher were more frequent in the zipalertinib arm (87% vs. 54.4%), analysts believe the robust efficacy and potential mitigation strategies will outweigh the safety concerns.
Rapid ReadRapid Read
SSRIs and Ketamine Offer Distinct Approaches to PTSD Treatment, Differing in Mechanism and FDA Status

SSRIs and Ketamine Offer Distinct Approaches to PTSD Treatment, Differing in Mechanism and FDA Status

Selective Serotonin Reuptake Inhibitors (SSRIs) and ketamine therapy represent fundamentally different approaches to treating Post-Traumatic Stress Disorder (PTSD). SSRIs, such as sertraline and paroxetine, are FDA-approved and recommended as first-line treatments, working by gradually increasing serotonin levels in the brain over several weeks. In contrast, ketamine acts on the brain's glutamate system, promoting neuroplasticity and often showing symptom relief within about two weeks. Ketamine is currently used off-label for PTSD and is not recommended by major clinical guidelines due to lower-quality evidence, though it is considered when first-line treatments are insufficient. Clinical trials indicate SSRIs help approximately 58% of individuals respond, while real-world data for ketamine therapy report higher response and remission rates, though no head-to-head controlled trials have been conducted. SSRIs are less effective for combat-related PTSD, a particularly challenging form of the condition. Side ...
TrendlineTrendline
FDA Accepts Curi Bio's 3D Neuromuscular Junction Assay for ISTAND Program, Advancing Non-Animal Testing for Botulinum Toxin

FDA Accepts Curi Bio's 3D Neuromuscular Junction Assay for ISTAND Program, Advancing Non-Animal Testing for Botulinum Toxin

FDA Accepts Curi Bio's 3D Neuromuscular Junction Assay for ISTAND Program, Advancing Non-Animal Testing for Botulinum Toxin
Rapid ReadRapid Read
New Study Links GLP-1 Weight Loss Drugs to Rare Brain Condition

New Study Links GLP-1 Weight Loss Drugs to Rare Brain Condition

A recent Israeli study has identified a potential link between GLP-1 weight loss and diabetes drugs and a rare, serious brain condition called Wernicke encephalopathy. The study, which reviewed U.S. Food and Drug Administration’s adverse event reports and related literature, found 15 cases of Wernicke encephalopathy between 2023 and 2024 in individuals taking these medications. Wernicke encephalopathy is a life-threatening neurological disorder caused by a severe deficiency of vitamin B1, which can lead to permanent memory loss and an inability to form new memories. Experts emphasize that this condition is rare, with only 15 cases identified out of millions of people using GLP-1 drugs. Most of the reported cases involved patients experiencing gastrointestinal side effects such as vomiting, diarrhea, and loss of appetite, which can lead to malnutrition and vitamin B1 deficiency. The majority of these cases were associated with semaglutide-based drugs like Ozempic and Wegovy, or tirzepatide GLP-1s such as Ze...
TrendlineTrendline
WonderBiotics Daily Fiber Mix Reviewed for Efficacy and Low-FODMAP Suitability

WonderBiotics Daily Fiber Mix Reviewed for Efficacy and Low-FODMAP Suitability

WonderBiotics Daily Fiber Mix Reviewed for Efficacy and Low-FODMAP Suitability
TrendlineTrendline
Wellness Influencers Promote Berberine as "Nature's Ozempic" in the U.S., Despite Traditional Use

Wellness Influencers Promote Berberine as "Nature's Ozempic" in the U.S., Despite Traditional Use

Wellness Influencers Promote Berberine as "Nature's Ozempic" in the U.S., Despite Traditional Use